文献速递肾移植

靶向递送IL-21中和纳米药物至淋巴结和肾移植物的作用

Targeted delivery of IL-21 neutralizing nanotherapeutics to lymph nodes and kidney allografts attenuates B cell alloimmunity.
PubMed 文献 · Kidney Int · 2025-04-21

本研究针对肾移植后抗体介导排斥反应缺乏特异性治疗的问题,发现排斥肾脏中形成源自宿主细胞的高内皮微静脉样结构,并据此开发靶向该结构的纳米递送系统,将IL-21中和抗体优先递送至引流淋巴结和肾移植物。结果显示该策略改善移植物功能与受体存活,减少同种反应性B细胞应答、供体特异性抗体产生及ABMR样病变,为选择性靶向效应部位减轻B细胞同种免疫提供治疗策略。

要点

  • 排斥肾脏中形成宿主来源的高内皮微静脉样结构。
  • 靶向高内皮微静脉的纳米递送系统可同时递送药物至引流淋巴结和肾移植物。
  • 递送IL-21中和抗体改善移植物功能和受体存活,减少B细胞同种免疫。

核心结论

  • 靶向高内皮微静脉递送IL-21中和纳米药物可减轻B细胞同种免疫并改善肾移植结局。

研究设计与样本

  • 实验性研究,开发靶向高内皮微静脉的纳米递送系统并在肾移植模型中评价。

主要发现

  • 排斥肾脏中形成源自宿主细胞的高内皮微静脉样结构。
  • NP-HEV[αIL21]优先递送至引流淋巴结和肾移植物,改善移植物功能与受体存活。
  • NP-HEV[αIL21]减少同种反应性B细胞应答、供体特异性抗体产生及ABMR样病变。

临床怎么用

  • 提供一种选择性靶向效应部位以减轻B细胞同种免疫、限制全身免疫抑制影响的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Antibody-mediated rejection (ABMR) after allogeneic kidney transplantation is a substantial clinical problem for which there are no specific treatments. High endothelial venules (HEV) are specialized veins which are normally present only in lymph nodes (LN) facilitating immune cell entry. Here, we show that kidneys undergoing rejection develop HEV-like structures derived from host cells. METHODS: We developed a nano-delivery system targeting HEVs to simultaneously deliver therapeutics to draining LN and kidney allografts. RESULTS: Using this system, we preferentially delivered IL-21 neutralizing antibody (NP-HEV[αIL21]) to draining LN and kidney allografts resulting in improved graft function and recipient survival. The NP-HEV[αIL21] system also decreased alloreactive B cell responses, donor-specific antibody production, and ABMR-like lesions in kidney grafts. CONCLUSIONS: Our study provides a therapeutic strategy to selectively target distinct effector sites to attenuate B-cell alloimmunity while limiting effects of broad systemic immunosuppression in kidney transplantation.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Zhang H, Sabiu G, Jung S, et al. Targeted delivery of IL-21 neutralizing nanotherapeutics to lymph nodes and kidney allografts attenuates B cell alloimmunity. Kidney Int. 2025. PMID: 40268164. doi:10.1016/j.kint.2025.03.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。